听力损失流行病学研究中的神经保护因子与听力障碍发病
该基于人群的纵向研究纳入1088名基线无听力障碍的成人,随访约16年,检测基线血清醛固酮、胰岛素样生长因子1(IGF1)和脑源性神经营养因子(BDNF)水平,分析其与听力障碍发病及纯音平均听阈变化的关系。结果显示,三种生物标志物最低五分位与最高五分位相比,均与听力障碍风险及听阈变化无显著关联。
要点
- 16年听力障碍累积发病率为54.9%,男性61.1%高于女性52.1%。
- 醛固酮、IGF1、BDNF最低五分位与最高五分位相比,与听力障碍风险无显著关联。
- 上述生物标志物水平亦未显著影响纯音平均听阈变化。
核心结论
- 在本研究中,醛固酮、IGF1和BDNF与年龄相关听力损失风险降低无关。
研究设计与样本
- 听力损失流行病学研究是始于1993年的基于人群的纵向老化研究,地点为威斯康星州比弗丹。
- 本分析的基线为1998至2000年阶段,随访检查约每5年一次,最近一次为2013至2016年。
- 听力采用纯音测听测量,听力障碍定义为任一侧耳纯音平均听阈(PTA)大于25 dB HL。
- 基线血清样本于2017年用于检测生物标志物,分析纳入1088名有听力障碍风险的参与者(69.3%为女性),平均基线年龄63.8岁(标准差7.0)。
主要发现
- 16年听力障碍累积发病率为54.9%,男性61.1%高于女性52.1%。
- 在年龄和性别调整模型中,醛固酮最低五分位与最高五分位相比,听力障碍风险HR=1.06(95%CI 0.82-1.37)。
- IGF1最低五分位与最高五分位相比,HR=0.92(95%CI 0.71-1.19),与听力障碍风险无显著关联。
- BDNF最低五分位与最高五分位相比,HR=0.86(95%CI 0.66-1.12),与听力障碍风险无显著关联。
- 纯音平均听阈变化同样未受生物标志物水平影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hearing impairment (HI) is common in aging adults. Aldosterone, insulin-like growth factor (IGF1), and brain-derived neurotrophic factor (BDNF) have been identified as potentially protective of hearing. The present study aims to investigate these relationships. METHODS: The Epidemiology of Hearing Loss Study is a longitudinal population-based study of aging in Beaver Dam, Wisconsin, that began in 1993. Baseline for the present investigation is the 1998 to 2000 phase. Follow-up exams occurred approximately every 5 years, with the most recent occurring from 2013 to 2016. Hearing was measured by pure-tone audiometry. HI was defined as a pure tone average (PTA) > 25 decibels hearing level in either ear. Change in PTA was the difference between follow-up examinations and baseline. Baseline serum samples were used to measure biomarkers in 2017. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated to assess the effect of biomarker levels in the lowest quintile (Q1) versus the highest (Q5) on incident HI and PTA change. RESULTS: There were 1,088 participants (69.3% women) at risk of HI included in analyses. The mean baseline age was 63.8 years (standard deviation = 7.0). The 16-year incidence of HI was 54.9% and was higher in men (61.1%) than women (52.1%). In age- and sex-adjusted models, aldosterone (HR = 1.06, 95% CI = 0.82-1.37), IGF1 (HR = 0.92, 95% CI = 0.71-1.19), and BDNF (HR = 0.86, 95% CI = 0.66-1.12) levels were not associated with risk of HI. PTA change was similarly not affected by biomarker levels. CONCLUSION: Aldosterone, IGF1, and BDNF were not associated with decreased risk of age-related hearing loss in this study. LEVEL OF EVIDENCE: 2b Laryngoscope, 129:2178-2183, 2019.
引用
- Paulsen AJ, Cruickshanks KJ, Pinto A, et al. Neuroprotective factors and incident hearing impairment in the epidemiology of hearing loss study. Laryngoscope. 2019. PMID: 30698838. doi:10.1002/lary.27847
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。